Standard
Epicensus : The Drive to Elevating the Standard of Care for Patients with Psoriasis. / Thomsen, Simon Francis; Corazza, Valeria; Augustin, Matthias; Lazaridou, Elizabeth; Puig, Lluís; Guillevin, Loïc.
I:
Dermatology and Therapy, 2024.
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
Thomsen, SF, Corazza, V, Augustin, M, Lazaridou, E, Puig, L & Guillevin, L 2024, '
Epicensus: The Drive to Elevating the Standard of Care for Patients with Psoriasis',
Dermatology and Therapy.
https://doi.org/10.1007/s13555-024-01192-2
APA
Thomsen, S. F., Corazza, V., Augustin, M., Lazaridou, E., Puig, L., & Guillevin, L. (2024).
Epicensus: The Drive to Elevating the Standard of Care for Patients with Psoriasis.
Dermatology and Therapy.
https://doi.org/10.1007/s13555-024-01192-2
Vancouver
Thomsen SF, Corazza V, Augustin M, Lazaridou E, Puig L, Guillevin L.
Epicensus: The Drive to Elevating the Standard of Care for Patients with Psoriasis.
Dermatology and Therapy. 2024.
https://doi.org/10.1007/s13555-024-01192-2
Author
Thomsen, Simon Francis ; Corazza, Valeria ; Augustin, Matthias ; Lazaridou, Elizabeth ; Puig, Lluís ; Guillevin, Loïc. / Epicensus : The Drive to Elevating the Standard of Care for Patients with Psoriasis. I: Dermatology and Therapy. 2024.
Bibtex
@article{92d28f0c37bb4c7b92e3c839a6e670b0,
title = "Epicensus: The Drive to Elevating the Standard of Care for Patients with Psoriasis",
keywords = "Multistakeholder, Psoriasis, Standard of care",
author = "Thomsen, {Simon Francis} and Valeria Corazza and Matthias Augustin and Elizabeth Lazaridou and Llu{\'i}s Puig and Lo{\"i}c Guillevin",
note = "Funding Information: Medical writing support was provided by Juma Akhtar, Ogilvy Health, London, UK, and funded by UCB Pharma. Funding Information: The Epicensus programme (including the development of the publication) was funded by UCB Pharma. The Rapid Service Fee was also funded by UCB Pharma. Funding Information: Simon Francis Thomsen has received research support from Janssen, LEO Pharma, Novartis and UCB; and has served on advisory boards for Almirall, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, UCB, Union Pharmaceuticals; and as a speaker for LEO Pharma, Novartis, Symphogen and UCB and has been the recipient of a travel grant to GUF and EADV from Novartis. Valeria Corazza has no other conflicts of interest to declare. Matthias Augustin has received consulting fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Hexal, Janssen, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, UCB Pharma and Xenoport. Elizabeth Lazaridou has received research grants to her department from AbbVie, Genesis Pharma, Janssen, LEO, Lilly, Novartis, Pfizer and UCB; honoraria for activities such as lectures/presentations/speaker bureaus from AbbVie, Genesis Pharma, Janssen, LEO, Lilly, Novartis and UCB; support for attending meetings and/or travel from AbbVie, Janssen, LEO, Lilly and UCB; and has participated on a Data Safety Monitoring Board or Advisory Board for AbbVie, Genesis Pharma, Janssen, LEO, Lilly, Novartis, Pfizer and UCB. Llu\u00EDs Puig has received grants/support paid to his institution from AbbVie, Almirall, Amgen, Boehringer Ingelheim, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi and UCB; consulting fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB; and payment/honoraria for activities such as lectures/presentations/speaker bureaus for Janssen, Lilly and Novartis. Lo\u00EFc Guillevin has served as a consultant for Boehringer Ingelheim, Certara, ESAI, GSK, Lilly, Novartis, Novo Nordisk, Roche, Sanofi, UCB Pharma. ",
year = "2024",
doi = "10.1007/s13555-024-01192-2",
language = "English",
journal = "Dermatology and Therapy",
issn = "2190-9172",
publisher = "Springer Verlag",
}
RIS
TY - JOUR
T1 - Epicensus
T2 - The Drive to Elevating the Standard of Care for Patients with Psoriasis
AU - Thomsen, Simon Francis
AU - Corazza, Valeria
AU - Augustin, Matthias
AU - Lazaridou, Elizabeth
AU - Puig, Lluís
AU - Guillevin, Loïc
N1 - Funding Information:
Medical writing support was provided by Juma Akhtar, Ogilvy Health, London, UK, and funded by UCB Pharma.
Funding Information:
The Epicensus programme (including the development of the publication) was funded by UCB Pharma. The Rapid Service Fee was also funded by UCB Pharma.
Funding Information:
Simon Francis Thomsen has received research support from Janssen, LEO Pharma, Novartis and UCB; and has served on advisory boards for Almirall, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, UCB, Union Pharmaceuticals; and as a speaker for LEO Pharma, Novartis, Symphogen and UCB and has been the recipient of a travel grant to GUF and EADV from Novartis. Valeria Corazza has no other conflicts of interest to declare. Matthias Augustin has received consulting fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Hexal, Janssen, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, UCB Pharma and Xenoport. Elizabeth Lazaridou has received research grants to her department from AbbVie, Genesis Pharma, Janssen, LEO, Lilly, Novartis, Pfizer and UCB; honoraria for activities such as lectures/presentations/speaker bureaus from AbbVie, Genesis Pharma, Janssen, LEO, Lilly, Novartis and UCB; support for attending meetings and/or travel from AbbVie, Janssen, LEO, Lilly and UCB; and has participated on a Data Safety Monitoring Board or Advisory Board for AbbVie, Genesis Pharma, Janssen, LEO, Lilly, Novartis, Pfizer and UCB. Llu\u00EDs Puig has received grants/support paid to his institution from AbbVie, Almirall, Amgen, Boehringer Ingelheim, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi and UCB; consulting fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB; and payment/honoraria for activities such as lectures/presentations/speaker bureaus for Janssen, Lilly and Novartis. Lo\u00EFc Guillevin has served as a consultant for Boehringer Ingelheim, Certara, ESAI, GSK, Lilly, Novartis, Novo Nordisk, Roche, Sanofi, UCB Pharma.
PY - 2024
Y1 - 2024
KW - Multistakeholder
KW - Psoriasis
KW - Standard of care
U2 - 10.1007/s13555-024-01192-2
DO - 10.1007/s13555-024-01192-2
M3 - Comment/debate
C2 - 38896383
AN - SCOPUS:85196277337
JO - Dermatology and Therapy
JF - Dermatology and Therapy
SN - 2190-9172
ER -
